drugset
drugset / Trial / NCT07816302

Atomized Intranasal Ketorolac at 30 mg Versus 20 mg for the Treatment of Acute Pain in the Emergency Department

NCT07816302 ↗

Phase 3 Not yet recruiting 100 enrolled Tehran University of Medical Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to compare the analgesic effectiveness and side effects of intranasal ketorolac at 30 mg Versus 20 mg for the Treatment of Acute moderate and severe Pain in the Emergency Department.

Timeline

Start
2026-10-10
Primary completion
2027-03-30
Completion
2027-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Other / unclassified 20 mg Intranasal
Subject Ketorolac Other / unclassified 30 mg Intranasal

Indications

No indication recorded.